Selim ÇOLAK, Yunus NAZLI, Necmettin ÇOLAK, Ömer ÇAKIR

Heparin induced thrombocytopenia

Heparine bağlı trombositopeni (HBT) heparin tedavisinin nadir fakat ciddi bir protrombotik yan etkisidir. Bu durum platelet faktör 4 ve heparin komplekslerine karşı trombosit aktive edici antikorlar tarafından indüklenir. Tanı hastalık olasılığının klinik değerlendirmesi ve laboratuvar testlerine dayanmaktadır. Erken tanı, heparin kullanımının kesilmesi ve müteakiben alternatif antikoagülan ilaçlar ile tedavi trombüs oluşumu, ekstremite amputasyonu ve ölüm gibi ciddi komplikasyonların önlenmesi için önemli adımlardır. Bu derlemede, HBT'nin klinik özelliklerini tanımlamak ve onun yönetimi için mevcut verileri özetlemeyi amaçladık.

Heparine bağlı trombositopeni

Heparin-induced thrombocytopenia (HIT) is a rare but serious prothrombotic adverse effect of heparin treatment. It is induced by platelet-activating antibodies against complexes of platelet factor 4 and heparin. Diagnosis rests on a clinical assessment of disease probability and laboratory testing. Prompt diagnosis of HIT, discontinuation of heparin use, and subsequent treatment with alternative anticoagulant drugs are essential steps to prevent serious complications such as thrombus formation, limb amputation, and death. In this review, we describe the clinical features of HIT and to summarize the data available for its management.

PDF

___

Hammon JW, Hines MH. Cardiac Surgery in the Adult. In: Cohn LH, ed. Extracorporeal circulation. New York: McGraw-Hill Press, 2012:283-329.
Shore-lesserson L, Enriquezn LJ. Kaplan's Cardiac Anesthesia. In: Kaplan JA, Reich DL, Savino JS, ed. Coagulation monitoring. St. Luis, Missuiri: Elsevier Press, 2011:496-519.
Linkins LA, Dans AL, Moores LK, et al. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e495-530.
Coutre S. Heparin induced thrombocytopenia. Nov 2012. http://www.uptodate.com/contents/heparin-induced-thrombocytopenia
Warkentin TE, Eikelboom JW. Who is (still) getting HIT? Chest 2007;131:1620-1622.
Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012;159:528-540.
http://www.thd.org.tr/thdData/Books/130/bolum-ii-heparin-iliskili-trombositopeni-hit-tani-ve-tedavi-kilavuzu
Hess CN, Becker RC, Alexander JH, Lopes RD. Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. J Thromb Thrombolysis 2012;34: 552-561.
Napolitano LM, Warkentin TE, Almahameed A, Nasraway SA. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med 2006; 34:2898-2911.
Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83: 572-577.
Dyke CM, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparininduced thrombocytopenia or antiplatelet factor four/ heparin antibodies. Ann Thorac Surg 2007;84:836-839.